



# ENTHEON

A New Dimension in Addiction Treatment





# Table of Contents

The Situation	5
The Entheon Solution	13
The Molecule – DMT	17
The Entheon Treatment	24
Research (& Development)	31
Partnerships, Acquisitions, & Investment Strategy	34
The Team	39
Financials	43

ENTHEON

# *A NEW DIMENSION IN ADDICTION TREATMENT*






# A Trillion Dollar Problem

A 2018 Lancet study, concluded that mental disorders, including addiction are on the rise and will cost global economy \$16 trillion by 2030.






ENTHEON



CORPORATE PRESENTATION

# The Situation



## THE GLOBAL ADDICTION CRISIS

**35M**

**People who suffer from drug  
dependence globally**

**166K**

**Overdose-related fatalities  
reported annually**



## SIGNIFICANT UNMET NEED

**“21.2 million Americans have a substance use disorder. In 2018, just 11% of those patients received the treatment they needed.”**

Association of American Medical Colleges



# Addiction: The Epidemic of Our Times

The current treatment model is not equipped to handle an exponentially growing crisis

	Deaths	Instances	Receive Treatment
Alcohol	88,000 (3 <sup>rd</sup> leading cause of preventable death in the US)	46,802 (US, 2018)	480,000 (US/every year)
Opiates	14.4 million adults in the US	2.1 million (US); 13.2 million (Globally)	34.2 million adults (US); 16 million live with a smoking-related disease
Smoking	4.4% (2015)	10% (Globally)	Cessation interventions widely available



## Current Treatments Lack Efficacy

- + Low-efficacy, High unpredictability and Prohibitive cost structure
- + Coping mechanisms rather than addressing underlying neurological and emotional causes.

Residential Treatment	12 Steps	MAT	Smoking Cessation
Efficacy as low as 5% Costly: \$5000- \$30,000/month	Efficacy as low as 5% Barriers to entry & access issues for many	Proven efficacy In the long-run, one substance is being replaced with another  Does not address core, motivating factors of SUD	Success of smoking replacement and other interventions as low as 20%

# Current Treatments Lack Efficacy

Substance Use is a complex disorder that, in many cases, does not fit into the standards set by modern medicine, which often serve as coping mechanisms rather than addressing underlying neurological and emotional causes.

## Challenges:

- + Complicated diagnosis, developed over time
- + Removal of substance does not guarantee abstinence
- + The root is thought to be psychological and emotional in nature, rather than purely habitual
- + Solutions must be targeted at psychological and emotional causes.




## A WORLD GONE WRONG

**When it comes to treating addiction, the rate of success is so low that society has been conditioned to accept – and even expect - failure.**

**This manner of thinking is both unacceptable and counterproductive. There is a need for an alternative approach, that addresses the human cost of addiction for individuals, families and society at large.**






ENTHEON



CORPORATE PRESENTATION


# The Entheon Solution




WHY ENTHEON?



**Entheon is powered by an  
unwavering commitment to  
significantly improve the odds  
of beating addiction.**





## WHY ENTHEON?

Leveraging emerging bio-technology, we are pioneering a leading-edge addiction recovery solution that harnesses and optimizes the therapeutic potential of patient-centric psychedelic medicine to remedy the underlying causes of Substance Use Disorder.

Focusing primarily on the powerful DMT molecule and its therapeutic potential, Entheon exists to invert the addiction recovery ratio, turning the ‘untreatable case’ and ‘lost cause’ from the norm to the exception.







# A Patient-centric & Personalized System of Psychedelic Medicine

+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
+	+	+	+	+	+	+	+	+	+	+	+	15	+	+	+
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

## + Preparation



## + Intra Experience



## + Post-therapy


Clinical tools to optimize prescriptive decisions

- Genetic biomarkers
- EEG biomarkers

Alerts and feedback for physicians & clinicians based on real-time analysis of EEG

Analysis of experience and on-going change over time

Long-term patient tracking and future therapy optimization




ENTHEON



CORPORATE PRESENTATION

# The Molecule



## WHAT IS DMT?

**DMT is one of the classic psychedelics, along with mescaline, LSD, and psilocybin. All are serotonin 5-HT2A receptor agonists (serotonergic hallucinogens) and share similar effects.**

### DMT is the Most Powerful of the Classic Psychedelics

Used therapeutically for hundreds of years in the form of ayahuasca + Scientifically studied from at least the 1950s onward + Present throughout the plant kingdom + Safe in humans & endogenous + Short acting




## DMT disrupts the Default Mode Network (DMN)


### DMN

The way our brain responds  
to stimuli based on  
ingrained patterns

- Beliefs
- Values
- Ethics
- Reactions
- Habits




# DMT




**N,N-Dimethyltryptamine (DMT)**  
an introspective psychedelic compound

**Standard  
Brain  
Activity**



**DMT  
Brain  
Activity**



# DMT


## The Psychedelic Experience

Although the DMT state is highly subjective many experiencers report common phenomenon

- Unusually vivid visual imagery and somatic effects
- A wide and powerful range of emotions
- Deep clarity and insight into one's life and relationships

## Perspectives & possibilities

- Dismantles deeply held beliefs
- Provides breakthrough clarity
- Gravitational pull to the positive / constructive





# Limitations of Other Molecules & Compounds

## Ayahuasca, Psilocybin & LSD

- + Long duration (6-8hrs)
- + Difficult to scale
- + Limited means of ending a negative adverse reaction
- + Lack of precise dose control

## DMT

- + Shorter session length
- + Higher patient throughput & access
- + Ability to end session if too intense
- + Titrate/modify dose if required

+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+

ENTHEON



CORPORATE PRESENTATION

# The Entheon Treatment



# The Psychedelic patient journey is not an isolated event

From physician assessment, to analysis of the psychedelic experience, as well as post therapy tracking and support, Entheon is developing tools to support all stages of the patient's journey.

Increased safety

Precision dosing

Optimized outcomes

# INDICATIONS

## Initial Target Indications

Nicotine cessation

Opioid-use disorder

Alcoholism

## Potential Indications

Behavioural addictions  
(e.g. food, gambling, sex)

Additional mental health indications



## THE ENTHEON INTELLIGENCE PLATFORM

**A highly individualized diagnostic and patient-monitoring system that ventures to enhance safety and optimize the outcomes at all stages of the patient journey.**

Developing a combination of genetic and predictive data analysis

+

Genetic testing to determine risk probability (HaluGen Life Sciences - slide 33)

+

Predictive biomarker response platform (in partnership with Divergence Neuro Tech)

+

EEG monitoring & AI provide real-time feedback during a psychedelic event





# Entheon's DMT Protocol

Continuous IV  
Infusion of DMT

Administered Within  
a Medical Context

Monitored/Controlled

## [ 1 CONTEXT AND INTENT ]

- + Trust
- + Beliefs
- + Trauma
- + Fears
- + Values
- + Past

## [ 2 DMT INFUSION ]

- + 60-90 minutes
- + Physician Assisted
- + Mind Altering Experience
- + Controlled Environment

## [ 3 INTEGRATION ]

- + Strengthen New Perspectives
- + Ongoing Support
- + Future Oriented



ENTHEON



CORPORATE PRESENTATION

# Research & Development



# Advancing our DMT protocol

The Centre for Human Drug Research (CHDR) to carry out a data-intensive study evaluating the pharmacodynamics, pharmacokinetics, and safety of a target-controlled intravenous infusion of DMT in humans.

GMP drug supply to be provided by PsyGen Labs.

## Clinical Trial - Estimated Milestones

- |      |    |  |
|------|----|--|
| 2021 | Q1 | <ul style="list-style-type: none"><li>+ Completion of Investigational Medicinal Product Dossier (IMPD)</li><li>+ Full clinical protocol completed in preparation for upcoming human trials at CHDR</li><li>+ Introductory meeting with Health Canada</li></ul> |
|      | Q2 | <ul style="list-style-type: none"><li>+ Introductory meeting with FDA</li><li>+ Drug formulation development; analytical method development; drug stability assays by CHDR</li><li>+ Finalize IMPD, Investigator's Brochure</li></ul>                          |
|      | Q4 | <ul style="list-style-type: none"><li>+ First patient recruitment</li><li>+ Clinical study to begin at CHDR</li></ul>  |
| 2022 | Q1 | <ul style="list-style-type: none"><li>+ End of study – last subject, last visit</li><li>+ First draft clinical report</li></ul>  |

# Estimated Clinical Trial Timeline

## Proof of Concept Human Study (Phase 1/2a equivalent)

**Location: Centre for Human Drug Research, Leiden, Netherlands**

**Timeline: 2020 Q4 – 2021 Q4 (projected)**

**Objectives:** Pharmacokinetic and pharmacodynamic assessment of DMT fumarate (GMP formulation) in otherwise healthy adult nicotine users. Establish optimal dose range and duration for therapeutic efficacy, including minimally effective and maximally tolerated doses.

## Nonclinical Studies (if required)

**Location: University of British Columbia or CRO**

**Timeline: 2020 Q3 – 2021 Q4 (concurrent with proof-of-concept study)**

**Objective:** To obtain safety and toxicity data for DMT in various in vitro and animal models.

## Nicotine Addiction Pilot Study in US (Phase 1/2a)

Location: Johns Hopkins University or similar US institution

**Timeline: Projected start 2022**

**Objective: Demonstrate safety and efficacy of DMT (fumarate, GMP formulation) administered via continuous intravenous infusion at doses and duration determined in proof-of-concept study.**

## Alcohol and Opiate Addiction Pilot Studies (Phase 1/2a)

**Location: Centre for Human Drug Research, Leiden, Netherlands**

### Timeline: 2022-2023

**Objective: Translation of DMT therapeutic protocol to other forms of addiction.**

## Nicotine Addiction Multicenter Study (Phase 2b/3)

**Location: Worldwide clinics (under license)**

## Timeline: 2023-2024

**Objective:** Expansion of pilot study to multiple clinics to assess treatment outcomes in larger populations of nicotine users, including specific indications (e.g., COPD).

ENTHEON



CORPORATE PRESENTATION

# Partnership, Acquisition & Investment Strategy



## Entheon will continue advancing through strategic partnerships, investments and acquisitions.

These strategic milestones will expand Entheon's reach to enhance the personalized delivery of psychedelic assisted psychotherapy to a wide range of molecules and therapeutic applications.

**Together with expert partners, Entheon aims to ensure:**

- + Increase safety
- + Precision dosing
- + Optimized outcomes

ENTHEON



HALUGEN

## Halugen Life Sciences Inc. Acquisition

**Developing and commercializing a pre-screening test to identify genetic markers.**

- + Predict an individual's reaction to hallucinogenic drugs
- + Screen for potential side effects
- + Commercial product available early Q2
- + Can be expanded to include additional biomarkers

### **Key genotypes**

- + HTR2A – sensitivity to serotonergic psychedelics
- + CYP2B6- ketamine metabolic

### **Key genetic markers**

Near & long-term risk factors  
(e.g., psychosis & schizophrenia)

- + C4A
- + NRG1
- + DISC1





DIVERGENCE

## Partnership & SOW with Divergence Neuro Technologies Inc.

Co-developing a data-driven, cloud-based advanced biomarker model and predictive platform based on EEG analysis, AI and machine learning.

- + Designed to inform, modify, and optimize psychedelic-assisted therapy
- + Development of drug specific & phenotype biomarkers
- + Track changes over time





# Heading.

## Investment into Heading Health, LLC

Participated in a Series A Preferred Stock Financing

- + Provides exposure to US-based ketamine-assisted therapy space and Heading's full-suite of therapies and diagnostic tools for the treatment of mental health disorders, including the fully regulated and insurable Spravato<sup>®</sup> (esketamine) nasal spray for treatment-resistant depression.
- + Led by Dr. Steven Levine, experienced in operating and scaling psychiatric clinics, securing insurance coverage and pioneering the most efficient and effective breakthroughs in clinical research and technologies.
- + Provides guidance regarding clinical practice and, the permissioned use of data and biomarker capture devices both in general psychiatric practice and Ketamine treatments.






ENTHEON



CORPORATE PRESENTATION

# The Team





Timothy Ko

---

**CHIEF EXECUTIVE OFFICER**

Broad background of leading private ventures in different sectors



Andrew Hogle Ph.D., M.Sc.

---

**DIRECTOR OF OPERATIONS, CSO**

Adjunct professor of Pharmacology at the University of British Columbia



Brian Jahns, PharmD

---

**CHIEF BUSINESS OFFICER**

20+ years of biopharmaceutical industry experience



Brandon Schwabe CPA, CGA

---

**CHIEF FINANCIAL OFFICER**

A decade of professional experience in finance and accounting



Yaron Eshel

---

**PROJECT MANAGER**

Led clinical trials and worked with CRO's all over the world



Christopher Gondi Ph.D., M.Sc.

---

**BOARD MEMBER**

Depts. Of Medicine, Surgery and Pathology at the University of Illinois



Ruth Chun M.A., J.D.

---

**CHIEF FINANCIAL OFFICER**

A decade of professional experience in finance and accounting



Nancy Maher

---

**SPECIAL ADVISOR**

Data and regulatory affairs



**Matthew W. Johnson**

---

**Ph.D., M.Sc.**  
Professor of Psychiatry and  
Behavioral Sciences, Johns Hopkins



**Robin-Carhart Harris**

---

**Ph.D.**  
Head, The Psychedelic Research  
Group, Imperial College London



**Dennis McKenna**

---

**Ph.D.**  
Ethno-pharmacologist, research  
pharmacognosist, lecturer and author



**Christopher Timmerman**

---

**Ph.D.**  
Lead Researcher, The Psychedelic  
Research Group, Imperial College  
London



**Malin Vedøy Uthaug**

---

**Ph.D.**  
Research Assist., Centre for  
Psychedelic Research, Imperial College  
of London



**Kenneth Tupper**

---


**Ph.D.**  
Director, Substance Use Prevention &  
Harm Reduction, BC Ministry of Health




**Dr. Michael Walker**

---

Prof. Emeritus Anesthesiology,  
Pharmacology and Therapeutics,  
UBC



# Financials






## THE OPPORTUNITY

**“The psychedelic drugs market is projected to grow at a CAGR of 16.3% over the next eight years to reach \$6.85 billion by 2027.”**



Nov. 12, 2020  
Commenced trading  
on the CSE

CSE:	ENBI	Outstanding Shares	54,038,933
FSE:	1XU1	Fully diluted	67,569,604
OTC:	ENTBF	Current Cash Position	4.7 M CAD
Average daily volume (as of 1/22/2021)			701,903



ENTHEON  
ENTHEON  
ENTHEON  
ENTHEON

